Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IRX-2 in Early Stage Breast Cancer
NCT02950259Phase 1Completed
- Start
- Feb 2017
- Primary completion
- May 2019
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 1, open-label trial of citoplurikin in breast cancer and triple-negative breast cancer (TNBC) (2 arms). Primary endpoint: Safety of the IRX-2 Regimen. Started Feb 2017; status: completed.
02
Drugs
citoplurikin
03
Conditions
breast cancertriple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT02950259.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02950259.